{"organizations": [], "uuid": "bb0ea0851dc47905e2697df1859a824baee90134", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/09/28/roche-multiple-sclerosis-idUSL5N11Y0OA20150928", "country": "US", "title": "Roche drug succeeds in hard-to-treat form of MS", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "Roche drug succeeds in hard-to-treat form of MS | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-09-28T10:51:00.000+03:00", "replies_count": 0, "uuid": "bb0ea0851dc47905e2697df1859a824baee90134"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/09/28/roche-multiple-sclerosis-idUSL5N11Y0OA20150928", "ord_in_thread": 0, "title": "Roche drug succeeds in hard-to-treat form of MS", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Sept 28 Roche said on Monday its experimental drug ocrelizumab had proved effective against primary progressive multiple sclerosis in a keenly awaited final-stage clinical trial.\nThe injectable antibody medicine is the first product to show positive study results in both the hard-to-treat progressive form of the disease and more common relapsing forms, underscoring its multibillion-dollar sales potential.\n(Reporting by Ben Hirschler , editing by Louise Heavens)", "external_links": [], "published": "2015-09-28T10:51:00.000+03:00", "crawled": "2015-09-28T10:12:13.192+03:00", "highlightTitle": ""}